MondoA Is an Essential Glucose-Responsive Transcription Factor in Human Pancreatic β-Cells.
Diabetes · 2018
Last updated 2026-05-28In human pancreatic cells, a protein called MondoA responds to high blood sugar by moving into the cell nucleus and turning on genes like TXNIP, which is linked to diabetes. However, drugs that mimic GLP-1, such as Exendin-4, can block this process and reduce the activity of these genes. When MondoA is silenced, cells take up more glucose.
AI summary of the abstract below.
| Journal | Diabetes, 2018 |
|---|---|
| Citations | 35 |
| Relative citation ratio | 1.28 |
| NIH percentile | 59 |
| Molecules | — |
| Conditions studied | Type 2 Diabetes |
Abstract
Although the mechanisms by which glucose regulates insulin secretion from pancreatic β-cells are now well described, the way glucose modulates gene expression in such cells needs more understanding. Here, we demonstrate that MondoA, but not its paralog carbohydrate-responsive element-binding protein, is the predominant glucose-responsive transcription factor in human pancreatic β-EndoC-βH1 cells and in human islets. In high-glucose conditions, MondoA shuttles to the nucleus where it is required for the induction of the glucose-responsive genes arrestin domain-containing protein 4 (ARRDC4) and thioredoxin interacting protein (TXNIP), the latter being a protein strongly linked to β-cell dysfunction and diabetes. Importantly, increasing cAMP signaling in human β-cells, using forskolin or the glucagon-like peptide 1 mimetic Exendin-4, inhibits the shuttling of MondoA and potently inhibits TXNIP and ARRDC4 expression. Furthermore, we demonstrate that silencing MondoA expression improves glucose uptake in EndoC-βH1 cells. These results highlight MondoA as a novel target in β-cells that coordinates transcriptional response to elevated glucose levels.
Verbatim abstract via PubMed 29282201 ↗